The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2024
Synopsis
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at US$ 8816.2 million in 2023 and is anticipated to reach US$ 21340 million by 2030, witnessing a CAGR of 13.3% during the forecast period 2024-2030.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
This report aims to provide a comprehensive presentation of the global market for Glucagon Like Peptide-1 (GLP-1) Agonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon Like Peptide-1 (GLP-1) Agonists.
Report Scope
The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glucagon Like Peptide-1 (GLP-1) Agonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at US$ 8816.2 million in 2023 and is anticipated to reach US$ 21340 million by 2030, witnessing a CAGR of 13.3% during the forecast period 2024-2030.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
This report aims to provide a comprehensive presentation of the global market for Glucagon Like Peptide-1 (GLP-1) Agonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon Like Peptide-1 (GLP-1) Agonists.
Report Scope
The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glucagon Like Peptide-1 (GLP-1) Agonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
1.1 Product Overview and Scope of Glucagon Like Peptide-1 (GLP-1) Agonists
1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value Comparison by Type (2024-2030)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts
1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2019-2030
1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2019-2030
1.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competition by Manufacturers
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2019-2024)
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2019-2024)
2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Type & Application
2.7 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation and Trends
2.7.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue
2.7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario by Region
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019-2030
3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019-2024
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2025-2030
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2019-2030
3.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2019-2024
3.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2025-2030
3.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
3.4.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
3.5.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.6.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
3.6.3 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.7.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
3.7.3 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
3.8.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
3.8.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2030)
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030)
4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2030)
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030)
4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2030)
5 Segment by Application
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2030)
5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024)
5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030)
5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2030)
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Corporation Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Amylin
6.6.1 Amylin Corporation Information
6.6.2 Amylin Description and Business Overview
6.6.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
6.7.5 Amylin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Chain Analysis
7.2 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
7.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Marketing
7.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels
7.4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
7.5 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
8 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
8.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
8.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
